期刊文献+
共找到921篇文章
< 1 2 47 >
每页显示 20 50 100
Natural Products and Antiviral Resistance
1
作者 Erute Magdalene Adongbede Janak Raj Khatiwada +1 位作者 Rishipal Rastrapal Bansode Leonard Lamont Williams 《Advances in Microbiology》 CAS 2024年第7期366-388,共23页
Viral diseases are minacious with the potential for causing pandemics and treatment is complicated because of their inherent ability to mutate and become resistant to drugs. Antiviral drug resistance is a persistent p... Viral diseases are minacious with the potential for causing pandemics and treatment is complicated because of their inherent ability to mutate and become resistant to drugs. Antiviral drug resistance is a persistent problem that needs continuous attention by scientists, medical professionals, and government agencies. To solve the problem, an in-depth understanding of the intricate interplay between causes of antiviral drug resistance and potential new drugs specifically natural products is imperative in the interest and safety of public health. This review delves into natural product as reservoir for antiviral agents with the peculiar potentials for addressing the complexities associated with multi-drug resistant and emerging viral strains. An evaluation of the mechanisms underlying antiviral drug activity, antiviral drug resistance is addressed, with emphasis on production of broad-spectrum antiviral agents from natural sources. There is a need for continued natural product-based research, identification of new species and novel compounds. 展开更多
关键词 Drug Resistance Resistance Mechanisms PHYTOCHEMICALS Broad-Spectrum drugs antiviral Agents
下载PDF
Distribution and impacts on the geological environment of antiviral drugs in major waters of Wuhan,China 被引量:1
2
作者 Jun He Tong Feng +7 位作者 Liang Tao Yue-e Peng Lei Tong Xin-wen Zhao Xin Shao Lin-ya Xu Yan-lin Yang Yong-bo Zhao 《China Geology》 CAS 2022年第3期402-410,共9页
This study investigated water samples collected from the surface water and groundwater in Wuhan City,Hubei Province,China in different stages of the outbreak of the coronavirus disease 2019(hereinafter referred to as ... This study investigated water samples collected from the surface water and groundwater in Wuhan City,Hubei Province,China in different stages of the outbreak of the coronavirus disease 2019(hereinafter referred to as COVID-19)in the city,aiming to determine the distribution characteristics of antiviral drugs in the city’s waters.The results are as follows.The main hydrochemical type of surface water and groundwater in Wuhan was Ca-HCO3.The major chemical components in the groundwater had higher concentrations and spatial variability than those in the surface water.Two antiviral drugs and two glucocorticoids were detected in the surface water,groundwater,and sewage during the COVID-19 outbreak.Among them,chloroquine phosphate and cortisone had higher detection rates of 32.26%and 25.80%,respectively in all samples.The concentrations of residual drugs in East Lake were higher than those in other waters.The main drug detected in the waters in the later stage of the COVID-19 outbreak in Wuhan was chloroquine phosphate,whose detection rates in the surface water and the groundwater were 53.85%and 28.57%,respectively.Moreover,the detection rate and concentration of chloroquine phosphate were higher in East Lake than in Huangjia Lake.The groundwater containing chloroquine phosphate was mainly distributed along the river areas where the groundwater was highly vulnerable.The residual drugs in the surface water and the groundwater had lower concentrations in the late stage of the COVID-19 outbreak than in the middle of the outbreak,and they have not yet caused any negative impacts on the ecological environment. 展开更多
关键词 Water environment antiviral drugs COVID-19 GROUNDWATER Urban geological survey engineering Envionment geological survey engineering WUHAN Hubei Province China
下载PDF
Prevention and Treatment of KSHV-associated Diseases with Antiviral Drugs 被引量:1
3
作者 Ren-rong TIAN Qing-jiao LIAO Xulin CHEN 《Virologica Sinica》 SCIE CAS CSCD 2008年第6期486-495,共10页
Kaposi’s sarcoma-associated herpesvirus (KSHV) was first identified as the etiologic agent of Kaposi’s sarcoma (KS) in 1994. KSHV infection is necessary,but not sufficient for the development of Kaposi sarcoma (KS),... Kaposi’s sarcoma-associated herpesvirus (KSHV) was first identified as the etiologic agent of Kaposi’s sarcoma (KS) in 1994. KSHV infection is necessary,but not sufficient for the development of Kaposi sarcoma (KS),primary effusion lymphoma (PEL),and multicentric Castleman disease (MCD). Advances in the prevention and treatment of KSHV-associated Diseases have been achieved,even though current treatment options are ineffective,or toxic to many affected persons. The identification of new targets for potential future therapies and the randomized trial to evaluate the efficacy of new antivirals are required. 展开更多
关键词 antiviral drugs Kaposi's sarcoma-associated herpesvirus (KS HV) Kaposi's sarcoma (KS) Primaryeffusion lymphoma Multicentric castleman disease
下载PDF
Character of Frontier Orbitals of Antiviral Drugs: Candidate Drugs against Covid-19
4
作者 Yoshihiro Mizukami 《Open Journal of Physical Chemistry》 2020年第3期158-165,共8页
We performed density functional theory (DFT) calculations for ribonucleotides and active triphosphate metabolites of candidate drugs against Coronavirus disease 2019 (Covid-19). Frontier orbitals (highest occupied mol... We performed density functional theory (DFT) calculations for ribonucleotides and active triphosphate metabolites of candidate drugs against Coronavirus disease 2019 (Covid-19). Frontier orbitals (highest occupied molecular orbital and lowest unoccupied molecular</span><span style="font-family:""> </span><span style="font-family:""><span style="font-family:Verdana;">orbital) at optimized structure of each molecule were obtained. T-705RTP (active triphosphate metabolite of favipiravir) and cytidine triphosphate (CTP) have similar shapes of frontier orbitals. We also obtained similar shapes of frontier orbitals among dihydroxy GS-441524 triphosphate (GS-441524 is an active triphosphate metabolite of remdesivir) and adenosine triphosphate (ATP). From a theoretical </span><span style="font-family:Verdana;">viewpoint, we suggest T-705RTP is a CTP analogue and dihydroxy GS-441524</span><span style="font-family:Verdana;"> triphosphate is an</span></span><span style="font-family:""> </span><span style="font-family:Verdana;">ATP analogue. 展开更多
关键词 Covid-19 antiviral drugs Frontier Orbitals RIBONUCLEOTIDES
下载PDF
Efficacy and safety of oral Chinese herbal medicine combined with nucleoside antiviral drugs against recurrent genital herpes:a systematic review and meta-analysis
5
作者 Tian-Li Liu Tong Liu +5 位作者 Xi-Ming Jin Qing-Qing Shao Wen-Jia Wang Cong Huang Zhuo Chen Ping Yuan 《Traditional Medicine Research》 2022年第1期53-63,共11页
Background:To compare the efficacy and safety of Chinese herbal medicine combined with nucleoside antiviral drugs and nucleoside antiviral drugs alone in treating recurrent genital herpes.Methods:PubMed,Embase,Web of ... Background:To compare the efficacy and safety of Chinese herbal medicine combined with nucleoside antiviral drugs and nucleoside antiviral drugs alone in treating recurrent genital herpes.Methods:PubMed,Embase,Web of Science,Cochrane Library,Chinese Biomedical Literature Database,China National Knowledge Internet,VIP Database,and Wanfang Data were searched from inception to April 2021.Randomized controlled trials on the efficacy and safety of oral Chinese herbal medicine combined with nucleoside antiviral drugs for recurrent genital herpes were collected.All included trials were independently assessed by two reviewers with the Cochrane risk-of-bias tool,and a meta-analysis was conducted using Review Manager 5.4.Results:Compared with the use of nucleoside antiviral drugs alone,combination therapy with oral Chinese herbal medicine plus nucleoside antiviral drugs effectively reduced the herpes recurrence rate after the end of treatment(3 months:P=0.0002;6 months:P<0.00001;1 year:P<0.00001)and the number of recurrences each year(P<0.00001),improved the recurrent Genital Herpes Quality of Life Questionnaire score(P<0.00001),and regulated the levels of interferon-γ,interleukin-2,tumor necrosis factor-α,and T lymphocyte subsets in the peripheral blood,and the difference was statistically significant.Different subgroups reported mixed results with respect to the efficacy in the short term.The incidence of adverse reactions and the time of symptom disappearance between the two groups were not significantly different.Conclusion:Chinese herbal medicine combined with nucleoside antiviral drugs can effectively reduce the recurrence rate of recurrent genital herpes,improve the patient’s quality of life and enhance the body’s immunity.Considering the possible risk of publication bias,more high-quality randomized controlled trials are still needed to verify the conclusions of this article. 展开更多
关键词 recurrent genital herpes Chinese herbal medicine nucleoside antiviral drugs META-ANALYSIS
下载PDF
Effects of Fuzheng Huayu Capsules combined with nucleoside antiviral drugs on liver and kidney function, serum inflammatory factors, TLR-4, TGF-β1 and aspartate aminotransferase-platelet ratio index in patients with HBV infection and decompensated liver
6
作者 Hai-Ling Zhang Dong-Xue Mei +4 位作者 Shan Wang Jie Zhang Xiao-Zhong Jiang Yan-Min Zhang Bin Liu 《Journal of Hainan Medical University》 2020年第4期45-49,共5页
Objective:To investigate the effect of Fuzheng Huayu Capsule combined with nucleoside antiviral drugs on liver and kidney function,serum inflammatory factors,Toll-like receptor 4(TLR-4),transforming growth factorβ1(T... Objective:To investigate the effect of Fuzheng Huayu Capsule combined with nucleoside antiviral drugs on liver and kidney function,serum inflammatory factors,Toll-like receptor 4(TLR-4),transforming growth factorβ1(TGF-β1)And aspartate aminotransferase-platelet ratio index(APRI).Methods:A total of 144 patients with HBV infection and decompensated cirrhosis were selected.All patients were divided into control group and case group by random number table method,with 72 cases in each group.The control group was given conventional liver protection and antiviral therapy;the case group was supplemented with Fuzheng Huayu Capsule on the basis of treatment in the control group.The changes of liver and kidney function,serum inflammatory factors,TLR-4,TGF-β1 and APRI in the two groups were observed.Results:The total effective rate of the case group was 93.06%,higher than 76.32%of the control group(P<0.05).Case group HBV DNA negative rate,negative rate of hepatitis B virus surface antigen(HBsAg),negative rate of hepatitis B virus e antigen(HBeAg)were significantly higher than the control group(76.39%vs 59.72%,55.56%vs 31.94%,51.39%vs 29.17%),the difference was statistically significant(P<0.05).Alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),hyaluronic acid(HA),laminin(LN),typeⅢprocollagen after treatment(PCⅢ),typeⅣcollagen(CⅣ),inner diameter of portal vein,inner diameter of splenic vein,spleen thickness,resistance index,urea nitrogen(BUN),creatinine(Cr),interleukin-6(IL-6),interleukin-8(IL-8),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),TLR-4,TGF-β1,APRI are lower than before treatment,albumin(ALB)and renal blood The flow rate was higher than before treatment;liver function indicators,liver fibrosis indicators,liver and spleen imaging indicators,renal hemodynamic indicators,serum inflammatory factors,TLR-4 in the case group The improvement of TGF-β1 and APRI.Conclusion:Fuzheng Huayu Capsules combined with nucleoside antiviral drugs have a clear clinical effect on patients with HBV infection and decompensated liver cirrhosis,significantly improve the clinical symptoms of patients,improve liver and kidney function,reduce inflammatory factor production,and can effectively inhibit HBV replication.Certain promotion value is worthy of further clinical research. 展开更多
关键词 Fuzheng Huayu Nucleoside antiviral drugs DECOMPENSATED cirrhosis ASPARTATE aminotransferase-platelet RATIO INDEX
下载PDF
Effects of alprostadil combined with nucleoside antiviral drugs on liver function, liver fibrosis markers and serum inflammatory factors in patients with decompensated liver cirrhosis with HBV infection
7
作者 Jing-Chun Song Hai-Tao Zhang +1 位作者 Bin Liu Hui-Fang Sun 《Journal of Hainan Medical University》 2019年第8期36-40,共5页
Objective:To explore the Effects of alprostadil combined with nucleoside antiviral drugs on liver function, liver fibrosis markers and serum inflammatory factors in patients with decompensated liver cirrhosis with HBV... Objective:To explore the Effects of alprostadil combined with nucleoside antiviral drugs on liver function, liver fibrosis markers and serum inflammatory factors in patients with decompensated liver cirrhosis with HBV infection.Methods: 136 patients with decompensated cirrhosis of HBV infection who were hospitalized in Linxi Hospital of Kailuan General Hospital, Tangshan Infectious Disease Hospital and North China University of Technology Hospital from January to February 2018, 2017 were selected. All patients were divided into control group and case group by random number table method, 68 cases in each group. The control group was treated with routine liver protection and antiviral therapy, while the case group was treated with alprostadil on the basis of the control group. The changes of liver function, liver fibrosis, liver and spleen imaging indexes, anti-virus related indexes and inflammatory factors were observed before and after treatment in the two groups.Results: The total effective rate of the case group was 97.06%, which was significantly higher than that of the control group (85.29%), and the difference was statistically significant. The ALT, AST, TBIL, LN, HA, PCIII, CIV, portal vein diameter, spleen vein diameter, spleen thickness, IL-6, hs-CRP, TNF-α and TGF-β1 were significantly lower in the case group than in the control group. ALB, HBV DNA conversion rate, HBsAg negative rate, and HBeAg negative rate were significantly higher than the control group, the difference was statistically significant. Conclusion: Alprostadil combined with nucleoside antiviral drugs can significantly improve the decompensation of HBV infection Liver function in patients with cirrhosis, reduce the degree of liver fibrosis, inhibit the production of serum inflammatory factors, and can effectively inhibit HBV replication, clinical efficacy is significant, with certain clinical application value. 展开更多
关键词 ALPROSTADIL NUCLEOSIDE antiviral drugs DECOMPENSATED cirrhosis LIVER function LIVER fibrosis
下载PDF
直接抗病毒药物治疗失败的慢性丙型肝炎患者临床特点及基因型分析
8
作者 崔蕊 马杈 +2 位作者 杨天芬 周浩军 李萍萍 《肝脏》 2024年第8期943-946,共4页
目的探索直接抗病毒药物(DAA)治疗失败的慢性丙型肝炎(CHC)患者的临床特点及基因型特征。方法选取2021年9月至2022年12月咸阳市第一人民医院DAA治疗失败的患者28例,同时期DAA治疗成功者100例。酶法检测肝功能、PCR-反向杂交法检测HCV基... 目的探索直接抗病毒药物(DAA)治疗失败的慢性丙型肝炎(CHC)患者的临床特点及基因型特征。方法选取2021年9月至2022年12月咸阳市第一人民医院DAA治疗失败的患者28例,同时期DAA治疗成功者100例。酶法检测肝功能、PCR-反向杂交法检测HCV基因型、Sanger测序法检测耐药相关替代突变(RAS)片段,分析DAA观察组患者临床特征及基因型特点。结果失败组和有效组HCV RNA>105 IU/mL分别为23例(82.1%)、34例(34.0%),差异有统计学意义(χ^(2)=20.526,P=0.001)。DAA治疗失败组男性患者TBil、DBil分别为14.61(10.98,20.78)μmol/L、4.94(3.08,7.48)μmol/L,均高于女性患者的6.65(4.90,8.40)μmol/L、2.50(1.78,3.07)μmol/L(Z=-2.018和-2.456,均P=0.01)。纳入患者共检测出3种HCV基因型,分别为1b、2a及3b,有26例未测出基因型,失败组HCV 1b、2a及3b基因型分别为11例(39.3%)、6例(21.4%)及5例(17.8%),有效组分别为56例(56.0%)、15例(15.0%)及9例(9.0%)。失败组检测出NS5A和NS5B2种基因片段,但是RAS发生率不同。结论DAA治疗失败者会受性别、病毒载量、基因型以及RAS种类影响。 展开更多
关键词 抗病毒药物(DAA) 慢性丙型肝炎 基因型 耐药相关替代突变(RAS)
下载PDF
直接抗病毒药物治疗肾移植供者来源性HCV感染的疗效分析 被引量:1
9
作者 陈任杰 昌盛 +6 位作者 陈松 刘斌 宫念樵 陈刚 蒋继贫 陈知水 张伟杰 《实用器官移植电子杂志》 2024年第3期220-224,共5页
目的评估直接抗病毒药物(direct antiviral drugs,DAAs)治疗接受丙型肝炎病毒(hepatitis C virus,HCV)阳性供肾的HCV阴性肾移植受者的安全性及有效性。方法共纳入2018-2023年期间华中科技大学同济医学院附属同济医院器官移植研究所12例... 目的评估直接抗病毒药物(direct antiviral drugs,DAAs)治疗接受丙型肝炎病毒(hepatitis C virus,HCV)阳性供肾的HCV阴性肾移植受者的安全性及有效性。方法共纳入2018-2023年期间华中科技大学同济医学院附属同济医院器官移植研究所12例患者,其中10例于移植当天立即启动预防性应用DAAs方案,2例于移植后出现肝功能异常及检测出HCV RNA(+)后再予以抗病毒治疗。所有患者均应用12周索非布韦(sofosbuvir,SOF)/维帕他韦(velpatasvir,VEL)口服抗病毒药,并定期复查转氨酶、血肌酐、eGFR、药物浓度及病毒载量等来评估DAAs的疗效和安全性。结果10例预防性用药患者在完成SOF/VEL方案后出现1例治疗失败,检测其基因亚型为3b,其余9例均于停药后12周获得持续性病毒学应答(sustained virological response,SVR12)。初治失败患者在连续两次更换抗病毒方案后最终通过联合利巴韦林(ribavirin,RIB)的方案也实现了SVR12。2例治疗性患者术后1个月时检测到肝功能异常及较高水平病毒载量,立即启动DAAs治疗,在接受治疗后转氨酶水平均能迅速恢复正常并实现SVR12。初治失败患者在使用含利巴韦林抗病毒方案时出现了持续性胆红素升高,所有患者随访期间血肌酐、药物浓度水平均维持稳定。结论HCV阴性受者接受HCV阳性供肾在肾移植术后预防性或治疗性使用DAAs是安全有效的,针对HCV 3b亚型的泛基因型抗病毒方案可能出现治疗失败,初治失败后可选择含利巴韦林的联合抗病毒方案。 展开更多
关键词 肾移植 慢性丙型肝炎 直接抗病毒药 持续性病毒学应答 复发
下载PDF
猴痘病毒感染的神经系统表现研究进展 被引量:1
10
作者 狄晓萌 刘磊(综述) 王佳伟(审校) 《中风与神经疾病杂志》 CAS 2024年第2期99-102,F0002,共5页
在过去的一年内,猴痘的爆发已成为全球关注的问题。猴痘是猴痘病毒感染引起的人畜共患病,除典型的皮疹症状以外,猴痘病毒感染还可引起一系列神经系统表现,潜在的机制可能包括感染后免疫介导的神经系统损伤,以及病毒直接侵入神经系统。... 在过去的一年内,猴痘的爆发已成为全球关注的问题。猴痘是猴痘病毒感染引起的人畜共患病,除典型的皮疹症状以外,猴痘病毒感染还可引起一系列神经系统表现,潜在的机制可能包括感染后免疫介导的神经系统损伤,以及病毒直接侵入神经系统。本文围绕猴痘病毒感染的神经系统表现进行综述,以促进早期识别、诊断猴痘病毒感染神经系统并发症,及时采取相应的防治措施。 展开更多
关键词 猴痘病毒 神经系统 脑炎 急性播散性脑脊髓炎 疫苗 抗病毒药物
下载PDF
基于Nrf2/HO-1启动子筛选抗水生病毒药物的方法
11
作者 王靖雯 吴苗苗 +2 位作者 李莉娟 顾泽茂 袁军法 《水产学报》 CAS CSCD 北大核心 2024年第2期141-152,共12页
为建立基于Nrf2、HO-1启动子活性的抗病毒药物筛选方法,实验以胖头鱥上皮细胞系(FHM)为材料,构建Nrf2、HO-1启动子重组质粒,利用双荧光素酶报告系统检测不同浓度(0、3.1、6.3、12.5、25.0、50.0μg/mL)的白藜芦醇、水飞蓟宾、穿心莲内... 为建立基于Nrf2、HO-1启动子活性的抗病毒药物筛选方法,实验以胖头鱥上皮细胞系(FHM)为材料,构建Nrf2、HO-1启动子重组质粒,利用双荧光素酶报告系统检测不同浓度(0、3.1、6.3、12.5、25.0、50.0μg/mL)的白藜芦醇、水飞蓟宾、穿心莲内酯及姜黄素对启动子活性的影响,并利用鲤春病毒血症病毒(spring viremia of carp virus,SVCV)和蛙虹彩病毒(rana grylio iridovirus,RGV)验证阳性药物的抗病毒效果。结果显示,Nrf2、HO-1启动子序列中存在FOX家族、IRF家族等多种转录因子的结合位点,并分别存在1个和3个与甲基化相关的CpG岛。双荧光素酶报告实验显示,水飞蓟宾、穿心莲内酯及姜黄素可激活Nrf2、HO-1启动子。药物浓度梯度实验显示,6.3μg/mL的姜黄素和穿心莲内酯可显著上调Nrf2和HO-1的启动子活性。病毒感染后的细胞病变效应、病毒的复制及病毒滴度结果均表明姜黄素和穿心莲内酯可抑制SVCV和RGV的感染。综上,本实验建立的pGL3-Nrf2和pGL3-HO-1启动子报告质粒,可用于抗水生病毒药物的筛选,也为Nrf2、HO-1转录调控机制的研究提供了工具。 展开更多
关键词 水生病毒 胖头鱥上皮细胞(FHM) NRF2 HO-1 启动子 抗病毒药物筛选
下载PDF
肉桂醇提物对大口黑鲈虹彩病毒的体外抗病毒作用
12
作者 廖文钰 竺利波 +7 位作者 刘明珠 余庆 玉洁莹 陈嘉 韦云依 黄吉利 黄琳 李鹏飞 《广东海洋大学学报》 CAS CSCD 北大核心 2024年第3期17-24,共8页
【目的】探究肉桂醇提物在大口黑鲈(Micropterus salmoides)虹彩病毒(LMBV)感染中的抗病毒效果及作用机制,为开发抗LMBV药物提供参考。【方法】采用CCK-8试剂盒检测、结晶紫染色观察、实时荧光定量PCR(RT-qPCR)检测、病毒滴度[半数组织... 【目的】探究肉桂醇提物在大口黑鲈(Micropterus salmoides)虹彩病毒(LMBV)感染中的抗病毒效果及作用机制,为开发抗LMBV药物提供参考。【方法】采用CCK-8试剂盒检测、结晶紫染色观察、实时荧光定量PCR(RT-qPCR)检测、病毒滴度[半数组织培养感染剂量(TCID50)]测定等方法确定肉桂醇提物在胖头鱥肌肉细胞系(FHM)上的安全工作浓度,评估肉桂醇提物在细胞水平对LMBV的抗病毒效果,分析其抗LMBV机制。【结果】肉桂醇提物在≤12.5μg/mL的质量浓度范围内对FHM细胞无明显毒性。FHM细胞与LMBV以及质量浓度分别为12.5、6.25、3.125μg/mL肉桂醇提物共孵育后,细胞病变明显减少,结晶紫染色后可见活细胞数明显升高,MCP、ICP46基因的表达量显著降低(P<0.01),且抗病毒效果有剂量依赖性。12.5μg/mL肉桂醇提物与LMBV共孵育后接入FHM细胞,细胞中MCP、ICP46基因的相对表达量以及TCID_(50)极显著下降(P<0.01);FHM细胞与经肉桂醇提物处理的LMBV共孵育后,细胞中LMBV MCP和ICP46基因的相对表达量显著低于未用肉桂醇提物处理的LMBV感染组(P<0.01);在LMBV感染FHM细胞后,接入肉桂醇提物的FHM细胞中MCP和ICP46基因的相对表达量显著下降(P<0.05);在LMBV感染FHM细胞3 h后用肉桂醇提物处理8 h的FHM细胞中MCP和ICP46基因的相对表达量显著下调(P<0.05)。【结论】肉桂醇提物可降低LMBV的感染力,干扰LMBV侵染宿主细胞过程中的吸附、侵入及复制,有良好的抗LMBV作用,可作为环保、高效的抗LMBV渔用药物候选者。 展开更多
关键词 大口黑鲈 虹彩病毒 肉桂 抗病毒作用 渔用药物
下载PDF
抗新型冠状病毒小分子药物临床应用专家共识
13
作者 中华医学会细菌感染与耐药防治分会 国家呼吸医学中心 +2 位作者 国家呼吸系统疾病临床医学研究中心 钟南山 王贵强 《传染病信息》 2024年第3期193-203,共11页
新型冠状病毒(新冠病毒)感染虽已不再构成“国际关注的突发公共卫生事件”,但仍在全球范围内处于低水平流行。小分子口服药物是我国目前推荐的针对新冠病毒感染的主要抗病毒治疗方案。虽然国内已上市多种抗新冠病毒小分子药物,但目前尚... 新型冠状病毒(新冠病毒)感染虽已不再构成“国际关注的突发公共卫生事件”,但仍在全球范围内处于低水平流行。小分子口服药物是我国目前推荐的针对新冠病毒感染的主要抗病毒治疗方案。虽然国内已上市多种抗新冠病毒小分子药物,但目前尚无针对特殊人群的具体用药推荐。中华医学会细菌感染与耐药防治分会联合国家呼吸医学中心、国家呼吸系统疾病临床医学研究中心组织国内呼吸、病毒学、感染、重症、急诊、药学等各领域专家制订了本共识。本共识的主要内容包括7种抗新冠病毒小分子药物介绍,重点阐述了老年人群、合并慢性疾病人群、肿瘤患者、孕妇、儿童等14种特殊人群用药推荐,为临床医师规范用药提供建议。 展开更多
关键词 冠状病毒感染 抗病毒治疗 小分子药物 早期 专家共识
下载PDF
人腺病毒感染治疗的研究进展
14
作者 张雪芳 刘峰 《中国医药导报》 CAS 2024年第10期183-185,共3页
人腺病毒传染性强,可引起多个器官病变,部分人群感染后可发展为危重症,预后差,病死率高。目前临床上使用的抗腺病毒药物的疗效和安全性存在争议。近年来,越来越多的化合物和中药在细胞或动物实验中显现出显著的抗腺病毒活性及良好的安... 人腺病毒传染性强,可引起多个器官病变,部分人群感染后可发展为危重症,预后差,病死率高。目前临床上使用的抗腺病毒药物的疗效和安全性存在争议。近年来,越来越多的化合物和中药在细胞或动物实验中显现出显著的抗腺病毒活性及良好的安全性。此外,T细胞免疫疗法、抗病毒单克隆抗体疗法和腺病毒疫苗也被证实可有效对抗腺病毒感染。本综述对抗腺病毒领域的最新研究和进展进行总结,为新型抗腺病毒药物的研制和临床工作提供参考借鉴。 展开更多
关键词 人腺病毒 抗病毒治疗 药物 免疫疗法 疫苗
下载PDF
疱疹病毒利用宿主蛋白高效复制机理及其抑制剂研究进展
15
作者 田文骏 游婧铃 王晓佳 《中国兽医杂志》 CAS 北大核心 2024年第3期90-96,共7页
疱疹病毒的入侵、转录和蛋白合成等多个生命活动,都需要利用宿主细胞蛋白和微环境进行。该过程一般会导致细胞蛋白的合成和降解、修饰、细胞定位改变,以及与其他蛋白相互作用等一系列变化。本文从病毒感染引起的细胞凋亡和自噬体系、泛... 疱疹病毒的入侵、转录和蛋白合成等多个生命活动,都需要利用宿主细胞蛋白和微环境进行。该过程一般会导致细胞蛋白的合成和降解、修饰、细胞定位改变,以及与其他蛋白相互作用等一系列变化。本文从病毒感染引起的细胞凋亡和自噬体系、泛素-蛋白酶体系、核-质转运体系、生物合成体系和病毒诱导的先天免疫反应几个层面,综述病毒劫持或干扰细胞正常生命活动的研究进展,探讨病毒与宿主细胞的相互作用关系,并对目前抗疱疹病毒药物靶点和机制进行总结,以期为设计新型抗病毒制剂提供资料。 展开更多
关键词 疱疹病毒 细胞凋亡 细胞自噬 核质转运 蛋白翻译 抗病毒药物
下载PDF
伪狂犬病病毒荧光标签毒株构建及其在抗病毒药物筛选中的初步应用
16
作者 呙会会 张浩 +5 位作者 杨丹 旷燕 李亚菲 刘绍蒙 刘青芸 王湘如 《畜牧兽医学报》 CAS CSCD 北大核心 2024年第8期3600-3611,共12页
为筛选针对伪狂犬病病毒(pseudorabies virus,PRV)的有效抗病毒药物,本研究以PRV人源分离毒株hSD-1/2019和经典猪源流行毒株Ea为亲本病毒,采用同源重组技术将mCherry报告基因插入到PRV的UL 35基因终止子之前位点,构建了表达红色荧光蛋白... 为筛选针对伪狂犬病病毒(pseudorabies virus,PRV)的有效抗病毒药物,本研究以PRV人源分离毒株hSD-1/2019和经典猪源流行毒株Ea为亲本病毒,采用同源重组技术将mCherry报告基因插入到PRV的UL 35基因终止子之前位点,构建了表达红色荧光蛋白mCherry的荧光标签毒株PRV-mCherry。基于构建的荧光标签病毒,以荧光强度为指标,建立高通量药物筛选平台,对天然产物库中1621种化合物进行抗病毒药物筛选,并初步探索药物特性。结果表明,mCherry标签插入位置正确且稳定遗传,荧光标签毒株PRV-mCherry与亲本毒株在PK-15细胞上的增殖曲线趋势一致,且荧光强度可反映病毒增殖情况。使用PRV-mCherry从天然产物库中成功筛选出3种可在体外有效抑制PRV增殖的药物,根据测定的50%细胞毒性浓度和50%抑制浓度,计算出3种药物的选择指数范围为203.63~564.58μmol·L^(-1),表明其具有良好的成药性。本研究为临床防治PRV感染的抗病毒药物发掘提供了新的策略和思路。 展开更多
关键词 伪狂犬病病毒 人源分离株 荧光标签毒株 抗病毒药物
下载PDF
扶正化瘀片联合抗病毒药物治疗乙肝肝硬化失代偿期患者的临床疗效及对其肝脏硬度、肝纤维化的影响
17
作者 王万娥 谢夏阳 +4 位作者 翟雪珍 张青 王雨露 黎防 张颖 《世界中西医结合杂志》 2024年第3期561-567,573,共8页
目的观察扶正化瘀片联合抗病毒药物治疗乙肝肝硬化(Liver cirrhosisi,LC)失代偿期患者的临床疗效及对其肝脏硬度、肝纤维化的影响。方法选取2020年5月—2022年5月期间淮安市第四人民医院收治的乙肝LC失代偿期患者共260例,按随机数字表... 目的观察扶正化瘀片联合抗病毒药物治疗乙肝肝硬化(Liver cirrhosisi,LC)失代偿期患者的临床疗效及对其肝脏硬度、肝纤维化的影响。方法选取2020年5月—2022年5月期间淮安市第四人民医院收治的乙肝LC失代偿期患者共260例,按随机数字表法分为对照组和观察组,每组各130例。对照组给予恩替卡韦分散片治疗,观察组在对照组基础上加服扶正化瘀片,均治疗24周。观察比较两组患者治疗前后中医证候积分[胁痛、胁下痞块、面色晦暗、口干不欲饮、乏力]、肝功能[总胆红素(Total bilirubin,TBil)、谷草转氨酶(Alanine aminotransferase,AST)、谷丙转氨酶(Aspartate aminotransferase,ALT)、白蛋白(Albumin,ALB)]、血清肝纤四项[层黏连蛋白(Laminin,LN)、Ⅲ型前胶原(Procollagen typeⅢ,PCⅢ)、IV型胶原(IV collegen,CIV)、透明质酸(Hyaluronic acid,HA)]、肝脾影像学[脾静脉内径、门静脉内径、脾脏厚度、肝脏瞬时弹性硬度(Liver stiff-ness measurement,LSM)]及Th1/Th2型细胞因子[白细胞介素-4(Interleukin-4,IL-4)、白细胞介素-6(Interleukin-6,IL-6)、白细胞介素-18(Interleukin-18,IL-18)、干扰素-γ(Inferferon-γ,IFN-γ)]指标变化情况,评估抗病毒效果[乙肝病毒脱氧核糖核酸(Hepatitis B virus-deoxyribonucleic acid,HBV-DNA)载量及转阴率、乙肝e抗原(Hepatitis B e antigens,HBeAg)转阴率]及临床疗效。结果治疗后两组患者胁痛、胁下痞块、面色晦暗、口干不欲饮和乏力证候积分均较治疗前降低,差异有统计学意义(P<0.05);且观察组胁痛、胁下痞块、面色晦暗、口干不欲饮和乏力证候积分均明显低于对照组,统计学有显著性差异(P<0.05)。治疗后两组患者肝功能TBil、AST、ALT水平均较治疗前降低,ALB水平均较治疗前升高,差异有统计学意义(P<0.05);且观察组TBil、AST、ALT水平均明显低于对照组,ALB水平明显高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者肝纤四项LN、PCШ、CIV和HA指标水平均较治疗前降低,差异有统计学意义(P<0.05);且观察组患者肝纤四项LN、PCШ、CIV和HA指标水平均明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者脾静脉内径、门静脉内径、脾脏厚度和LSM指标均较治疗前降低,差异有统计学意义(P<0.05);且观察组脾静脉内径、门静脉内径、脾脏厚度和LSM指标均明显低于对照组,差异有统计学意义(P<0.05)。治疗后观察组患者IL-4、IL-6水平较治疗前降低,IL-18、IFN-γ水平较治疗前升高,差异有统计学意义(P<0.05);对照组Th1/Th2型细胞因子水平与治疗前比较,差异无统计学意义(P>0.05);且观察组IL-4、IL-6水平明显低于对照组,IL-18、IFN-γ水平明显高于对照组,差异有统计学意义(P<0.05)。治疗后观察组HBV-DNA载量低于对照组。观察组HBV-DNA转阴率59.23%(77/130)和HBeAg转阴率56.15%(73/130)明显高于对照组41.54%(54/130)、38.46%(50/130),差异有统计学意义(P<0.05)。治疗后观察组总有效率93.85%(122/130)明显高于对照组81.54(106/130),差异有统计学意义(P<0.05)。结论扶正化瘀片与抗病毒药物联合治疗能够改善乙肝LC失代偿期患者症状和肝功能,降低肝脏硬度和肝纤维化程度,维持Th1/Th2型细胞因子平衡。 展开更多
关键词 扶正化瘀片 抗病毒药物 乙肝 肝硬化 失代偿期
下载PDF
人类肠道病毒的研究进展
18
作者 李晓涵 杨佳新 +2 位作者 唐煜斌 倪福顺 魏伟 《生物医学转化》 2024年第1期12-27,共16页
自1908年脊髓灰质炎病毒被鉴定以来,已发现超百种肠道病毒致病血清型,可引起手足口病、新生儿败血症样疾病、无菌性脑炎、急性弛缓性脊髓炎、呼吸系统疾病、急性出血性结膜炎等多种疾病。近年来,诸如EV-A71和EVD68等肠道病毒趋于全球化... 自1908年脊髓灰质炎病毒被鉴定以来,已发现超百种肠道病毒致病血清型,可引起手足口病、新生儿败血症样疾病、无菌性脑炎、急性弛缓性脊髓炎、呼吸系统疾病、急性出血性结膜炎等多种疾病。近年来,诸如EV-A71和EVD68等肠道病毒趋于全球化周期性流行,已成为公共卫生领域不可忽视的重要挑战之一。然而,当前针对肠道病毒的防控手段仍然非常有限,迫切需要深入探究肠道病毒致病的分子机制,为开发高效、安全、广谱的抗肠道病毒药物提供新靶点与新思路。本文通过对肠道病毒的分类、流行病学、结构、生命周期、病毒蛋白与宿主因子相互作用、并发症致病机制与临床治疗以及动物感染模型的确立与应用等方面进行系统的综述,旨在为肠道病毒防治提供理论参考依据,为肠道病毒的药物研发与疫苗储备库建设提供新的思路。 展开更多
关键词 肠道病毒 病毒-宿主互作 动物模型 临床症状 抗病毒药物
下载PDF
丙型肝炎病毒感染对胃肠道肿瘤患者接受术后辅助化疗的影响
19
作者 卫鑫 宋东峰 《临床医学研究与实践》 2024年第8期47-51,共5页
目的探索丙型肝炎病毒(HCV)感染对胃肠道肿瘤患者接受术后辅助化疗的影响。方法回顾性选取合并HCV感染手术后需要立即接受术后辅助化疗的胃肠道肿瘤患者为研究组(29例),选取HCV阴性并接受术后辅助化疗的胃肠道肿瘤患者为对照组(59例)。... 目的探索丙型肝炎病毒(HCV)感染对胃肠道肿瘤患者接受术后辅助化疗的影响。方法回顾性选取合并HCV感染手术后需要立即接受术后辅助化疗的胃肠道肿瘤患者为研究组(29例),选取HCV阴性并接受术后辅助化疗的胃肠道肿瘤患者为对照组(59例)。比较两组的一般资料和临床特征,分析HCV感染对胃肠道肿瘤患者接受术后辅助化疗的影响。结果研究组的基线谷丙转氨酶(ALT)水平高于对照组,化疗后的ALT水平升高更为显著(P<0.05)。研究组的严重不良事件(SAEs)及不良事件(AEs)的总发生率均高于对照组(P<0.05)。研究组在化疗期间出现化疗延期及化疗药物减量的概率明显高于对照组,差异具有统计学意义(P<0.05)。结论HCV阳性的胃肠道肿瘤患者在接受术后辅助化疗时更容易出现不良反应;HCV阳性阻碍化疗的顺利完成,应该予以密切监测。 展开更多
关键词 丙型肝炎病毒 胃肠道肿瘤 化疗 直接抗病毒药物 药物相互作用 谷丙转氨酶 严重不良事件
下载PDF
Efficacy and safety of carrimycin in ten patients with severe pneumonia following solid organ transplantation
20
作者 Xian-Quan Cui Lu-Wei Zhang +1 位作者 Peng Zhao Jing-Jing Feng 《World Journal of Clinical Cases》 SCIE 2024年第15期2542-2550,共9页
BACKGROUND The number of patients undergoing solid organ transplantation has increased annually.However,infections in solid organ transplant recipients can have a severe effect on patient survival owing to the continu... BACKGROUND The number of patients undergoing solid organ transplantation has increased annually.However,infections in solid organ transplant recipients can have a severe effect on patient survival owing to the continued use of immunosuppressants.Carrimycin is a novel macrolide antibiotic produced by genetically engineered streptomyces spiramyceticus harboring a 4’’-O-isovaleryltransferase gene(ist)from streptomyces thermotoleran.Carrimycin has good antibacterial and antiviral effects.However,no relevant studies have been conducted on the efficacy and safety of carrimycin in patients with severe pneumonia(SP)after solid organ transplantation.AIM To explore the efficacy and safety of carrimycin in patients with SP after solid organ transplantation to provide a medication reference for clinical treatment.METHODS In March 2022,ten patients with SP following solid-organ transplantation were treated at our hospital between January 2021 and March 2022.When the condition was critical and difficult to control with other drugs,carrimycin was administered.These ten patients'clinical features and treatment protocols were retrospectively analyzed,and the efficacy and safety of carrimycin for treating SP following solid organ transplantation were evaluated.RESULTS All ten patients were included in the analysis.Regarding etiological agent detection,there were three cases of fungal pneumonia,two cases of bacterial pneumonia,two cases of Pneumocystis pneumonia,and three cases of mixed infections.After treatment with carrimycin,the disease in seven patients significantly improved,the course of the disease was significantly shortened,fever was quickly controlled,chest computed tomography was significantly improved,and oxygenation was significantly improved.Finally,the patients were discharged after curing.One patient died of acute respiratory distress syndrome,and two patients discontinued treatment.CONCLUSION Carrimycin is a safe and effective treatment modality for SP following solid organ transplantation.Carrimycin may have antibacterial and antiviral effects in patients with SP following solid organ transplantation. 展开更多
关键词 Carrimycin Organ transplantation Severe pneumonia IMMUNOSUPPRESSANT INFECTION antiviral drugs
下载PDF
上一页 1 2 47 下一页 到第
使用帮助 返回顶部